Royal Jelly as a Strategy to Modulate Inflammation and Oxidative Stress in Patients With Systemic Arterial Hypertension
Recruiting · NCT06917131 · Interventional (participants receive a specific treatment) · Lead sponsor: Universidade Federal Fluminense
View the official record on ClinicalTrials.gov →Interventions studied
PlaceboRoyal Jelly
What this trial is about
The study aims to evaluate the effect of the royal jelly on inflammation and oxidative stress in participants with systemic arterial hypertension. A longitudinal double-blind randomized clinical trial will be carried out, involving hypertensive participants for two months.
Who can take part
Age range
18 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Diagnosis of stage 1 hypertension
- Regular treatment for more than 6 months
- No changes in medication doses during the last 3 months
Exclusion criteria
- Autoimmune diseases
- Infectious diseases
- Diabetes
- Chronic kidney disease
- Liver disease
- Cancer
- AIDS
- Pregnant women
- Use of catabolic drugs or antibiotics
- Use of antioxidant vitamin supplements, prebiotics, probiotics, or synbiotics
- Habitual intake of royal jelly
- Allergy to bee stings
- Acute myocardial infarction (AMI)
- Stroke (CVA)
Where it is running
1 location listed.
- Denise Mafra - Rio de Janeiro, Rio de Janeiro, Brazil